695 results on '"Brentjens, Renier J"'
Search Results
2. Author Correction: Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors
3. CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results
4. TYRP1 directed CAR T cells control tumor progression in preclinical melanoma models
5. Author Correction: Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy
6. Low toxicity and favorable overall survival in relapsed/refractory B-ALL following CAR T cells and CD34-selected T-cell depleted allogeneic hematopoietic cell transplant
7. CD103+ cDC1 and endogenous CD8+ T cells are necessary for improved CD40L-overexpressing CAR T cell antitumor function
8. Developing a membrane-proximal CD33-targeting CAR T cell
9. Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion
10. Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy
11. Engineering CAR-T cells to activate small-molecule drugs in situ
12. IL-18-secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models
13. Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult acute lymphoblastic leukemia
14. Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System
15. Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells
16. CAR T cell therapy: looking back and looking forward
17. Cytokine IL-36γ improves CAR T-cell functionality and induces endogenous antitumor response
18. Chimeric Antigen Receptor-T Cells for Leukemias in Adults: Methods, Data and Challenges
19. Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL
20. Engineering strategies to overcome the current roadblocks in CAR T cell therapy
21. CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma
22. Cytokine Release Syndrome Grade as a Predictive Marker for Infections in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated With Chimeric Antigen Receptor T Cells
23. Building a CAR Garage: Preparing for the Delivery of Commercial CAR T Cell Products at Memorial Sloan Kettering Cancer Center
24. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo
25. Tumor derived UBR5 promotes ovarian cancer growth and metastasis through inducing immunosuppressive macrophages
26. Supplementary Figure Legends from Optimization of T-cell Receptor–Modified T Cells for Cancer Therapy
27. Data from Excessive Costimulation Leads to Dysfunction of Adoptively Transferred T Cells
28. Supplementary Figure Legends from Excessive Costimulation Leads to Dysfunction of Adoptively Transferred T Cells
29. Figure S4 from Excessive Costimulation Leads to Dysfunction of Adoptively Transferred T Cells
30. Data from Optimization of T-cell Receptor–Modified T Cells for Cancer Therapy
31. Data from BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy
32. Supplementary Figures 1-8 from Optimization of T-cell Receptor–Modified T Cells for Cancer Therapy
33. Supplementary Data from BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy
34. Data from A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab
35. Supplementary Figures from A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab
36. Data from Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia
37. Figure S1, Figure S2, Figure S3, Figure S4 from Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia
38. Supplementary Material from A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab
39. Supplementary Tables from A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab
40. Table S1, Table S2, Table S3, Table S4 from Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia
41. Application of CAR T cells for the treatment of solid tumors
42. Chimeric Antigen Receptor-T Cells for Leukemias in Adults: Methods, Data and Challenges
43. Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells
44. Supplementary Data from Successful Eradication of Established Peritoneal Ovarian Tumors in SCID-Beige Mice following Adoptive Transfer of T Cells Genetically Targeted to the MUC16 Antigen
45. Data from Successful Eradication of Established Peritoneal Ovarian Tumors in SCID-Beige Mice following Adoptive Transfer of T Cells Genetically Targeted to the MUC16 Antigen
46. CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date
47. Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance
48. Author Correction: Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy
49. Immunotherapies in CLL
50. GPRC5D-Targeted CAR T Cells for Myeloma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.